This study demonstrates that TRA16 is highly expressed in approximately 90% of NSCLCs, in which over 71% of stage I NSCLC overexpress TRA16, which is not expressed in lung benign diseases and normal lung tissues, indicating its potential for NSCLC diagnosis, especially for early stage NSCLC. This evidence concerns the gene NR2C2AP and medical procedure.